logo

For the Inventor, By the Inventor

Carlsbad, CA, United States of America

Russell Dahl

This inventor holds 8 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Itherx Pharmaceuticals Inc., Burnham Institute for Medical Research, Icahn School of Medicine at Mount Sinai. Active years: 2005-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Russell Dahl. Retrieved from https://idiyas.com/inventor/russell-dahl-zvs9df5k

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8 

% Patents Active = 25.0

 

Average Co-Inventor Count = 6.3

ph-index = 4

Forward Citations = 51(Granted Patents)


Company Filing History:

goldMedal3 out of 3 
 
Itherx Pharmaceuticals Inc.
 patents
silverMedal2 out of 55 
 
Burnham Institute for Medical Research
 patents
bronzeMedal2 out of 538 
 
Icahn School of Medicine at Mount Sinai
 patents
4. 1 out of 1 
 
Deltagen Research Labs, LLC
 patent
5. 1 out of 164 
 
Icos Corporation
 patents
where one patent can have more than one assignee

Years Active: 2005-2019

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 10501453 - Benzothiazole or benzoxazole compounds as SUMO activators (2019-12-10),
2. 9845320 - Benzothiazole or benzoxazole compounds as sumo activators (2017-12-19),
3. 7919617 - Cytokine inhibitors (2011-04-05),
4. 7897599 - Cytokine inhibitors (2011-03-01),
5. 7888355 - Compositions and methods for inhibiting growth and metastasis of melanoma (2011-02-15),
6. 7776894 - Compositions and methods for inhibiting growth and metastasis of melanoma (2010-08-17),
7. 7749999 - Alpha-ketoamides and derivatives thereof (2010-07-06),
8. 6924284 - PARP inhibitors (2005-08-02),

Title: The Innovative Journey of Russell Dahl: Pioneering Sumo Activators in Medical Research

Introduction:

Russell Dahl, a renowned inventor based in Carlsbad, CA (US), has left a significant mark in the field of medical research with his groundbreaking inventions. With a total of 8 patents to his name, Dahl's contributions have ranged from cardiovascular treatments to addressing neurodegenerative disorders.

Latest Patents:

Dahl's latest patents involve Benzothiazole or benzoxazole compounds as SUMO activators. These activators play a crucial role in enhancing the SUMOylation of SERCA2a, presenting promising applications in treating heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral and bacterial infections, liver disease, inflammation, and various other medical conditions.

Career Highlights:

Throughout his career, Russell Dahl has been associated with esteemed organizations such as Itherx Pharmaceuticals Inc. and the Burnham Institute for Medical Research. His innovative spirit and dedication to advancing medical science have propelled him to the forefront of cutting-edge research in the industry.

Collaborations:

In his journey of innovation, Dahl has collaborated with notable individuals such as Erik Boman and Susana Conde Ceide. Together, they have synergized their expertise to drive forward groundbreaking research projects and bring revolutionary ideas to fruition.

Conclusion:

Russell Dahl's pioneering work in the development of SUMO activators stands as a testament to his unwavering commitment to improving healthcare outcomes and addressing a diverse range of medical challenges. His inventive spirit continues to inspire future generations of inventors and researchers in the quest for innovative solutions to complex health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…